VPTDF - Ventripoint Selected by Life Sciences Ontario as 2021 Success Story
(TheNewswire)
*** LSO Initiates Campaign to Inform Ontario MPPs ofActivity within the Sector ***
Toronto, Ontario – TheNewswire –November 24, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that Ventripoint will behighlighted as one of Life Sciences Ontario (LSO) 2021 Success Stories ( https://lifesciencesontario.ca/reports-and-publications/ ). The LSO campaign aims to highlightcompanies and institutions that are creating innovative solutions inthe life science sector.
The LSO is a member-funded, non-for-profit organizationthat works to advance advocacy and policy work, education andnetworking events, and support services for the life sciences sector.As part of the campaign, Ventripoint’s story will be distributed atLSO Queens Park meetings where MPPs are engaged on future policydevelopment as an example of innovation that improves healthcare in amore cost-effective manner.
"Ontario's life sciences industry is dedicated tobringing new innovations to improve the lives of all Canadians.Success stories, like Ventripoint Diagnostics, show how scientificdiscoveries can be turned into real-world solutions; while creatingjobs and prosperity here in Ontario," Dr. Jason Field, CEO, andPresident of Life Sciences Ontario.
The VMS+ is the first cost effective and accuratesystem for measuring the function all four chambers of the heart. Thisinitiative will help to bring brand awareness and spread the wordabout Ventripoint’s innovative solution to improve cardiac diagnosisfor everyone worldwide and especially for children.
About Life Sciences Ontario
LSO’s mission is to foster commercial success forOntario’s life sciences sector through advocacy and education, andpromoting the industry locally, nationally, and internationally. TheLSO works to increase the profile of Ontario’s Life Sciences sectorto secure economic and social prosperity. The organization’seducation around successful companies within the sector facilitateswill support the growth and development of the life sciencesector.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.